Search

Your search keyword '"Smeland S"' showing total 19 results
Start Over Author "Smeland S" Publisher elsevier bv
19 results on '"Smeland S"'

1. 503P The IMPRESS-Norway trial: Improving public cancer care by implementing precision cancer medicine in Norway

Author

Helland, A., primary, Tasken, K., additional, Russnes, H.E.G., additional, Fagereng, L., additional, Blix, E.S., additional, Brabrand, S., additional, Donnem, T., additional, Flobak, Å., additional, Gjertsen, B.T., additional, Haug, A., additional, Hovland, R., additional, Inpred, G., additional, Lonning, P.E., additional, Niehusmann, P., additional, Puco, K., additional, Samdal, E.S., additional, and Smeland, S., additional

Published
2022
Full Text
View/download PDF

2. 1315O Key learnings from building: A precision cancer medicine implementation initiative for Norway

Author

Tasken, K., primary, Russnes, H.G., additional, Aas, E., additional, Bjorge, L., additional, Blix, E.S., additional, Enerly, E., additional, Fagereng, L., additional, Flobak, Å., additional, Gilje, B., additional, Gjertsen, B.T., additional, Guren, T.K.K., additional, Heix, J., additional, Hovig, E., additional, Hovland, R., additional, Lonning, P.E., additional, Mæhle, P.M., additional, Nilsen, H.L., additional, Thoresen, S., additional, Smeland, S., additional, and Helland, A., additional

Published
2022
Full Text
View/download PDF

6. PT08.1: DNA Damage in Blood Cells in Relation to Chemotherapy and Nutritional Status in Colorectal Cancer Patients

Author

Kværner, A.S., primary, Minaguchia, J., additional, Yamaniac, N.E., additional, Henriksen, C., additional, Ræder, H., additional, Paur, I., additional, Henriksen, H.B., additional, Langleite, T.M., additional, Wiedswang, G., additional, Smeland, S., additional, Blomhoff, R., additional, Collins, A.R., additional, and Bøhn, S.K., additional

Published
2017
Full Text
View/download PDF

9. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment

Author

Whelan, J.S., primary, Bielack, S.S., additional, Marina, N., additional, Smeland, S., additional, Jovic, G., additional, Hook, J.M., additional, Krailo, M., additional, Anninga, J., additional, Butterfass-Bahloul, T., additional, Böhling, T., additional, Calaminus, G., additional, Capra, M., additional, Deffenbaugh, C., additional, Dhooge, C., additional, Eriksson, M., additional, Flanagan, A.M., additional, Gelderblom, H., additional, Goorin, A., additional, Gorlick, R., additional, Gosheger, G., additional, Grimer, R.J., additional, Hall, K.S., additional, Helmke, K., additional, Hogendoorn, P.C.W., additional, Jundt, G., additional, Kager, L., additional, Kuehne, T., additional, Lau, C.C., additional, Letson, G.D., additional, Meyer, J., additional, Meyers, P.A., additional, Morris, C., additional, Mottl, H., additional, Nadel, H., additional, Nagarajan, R., additional, Randall, R.L., additional, Schomberg, P., additional, Schwarz, R., additional, Teot, L.A., additional, Sydes, M.R., additional, Bernstein, M., additional, Pickering, James, additional, Joffe, Nicola, additional, Kevric, Matthias, additional, Sorg, Benjamin, additional, Villaluna, Doojduen, additional, Wang, Caroline, additional, Perisoglou, Martha, additional, Trani, Leonardo, additional, Potratz, Jenny, additional, Carrle, Dorothe, additional, Wilhelm, Miriam, additional, Zils, Katja, additional, and Teske, Carmen, additional

Published
2015
Full Text
View/download PDF

11. Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation

Author

Luksch, R., primary, Tienghi, A., additional, Hall, K. Sundby, additional, Fagioli, F., additional, Picci, P., additional, Barbieri, E., additional, Gandola, L., additional, Eriksson, M., additional, Ruggieri, P., additional, Daolio, P., additional, Lindholm, P., additional, Prete, A., additional, Bisogno, G., additional, Tamburini, A., additional, Grignani, G., additional, Abate, M.E., additional, Podda, M., additional, Smeland, S., additional, and Ferrari, S., additional

Published
2012
Full Text
View/download PDF

12. Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol

Author

Ferrari, S., primary, Sundby Hall, K., additional, Luksch, R., additional, Tienghi, A., additional, Wiebe, T., additional, Fagioli, F., additional, Alvegard, T.A., additional, Brach del Prever, A., additional, Tamburini, A., additional, Alberghini, M., additional, Gandola, L., additional, Mercuri, M., additional, Capanna, R., additional, Mapelli, S., additional, Prete, A., additional, Carli, M., additional, Picci, P., additional, Barbieri, E., additional, Bacci, G., additional, and Smeland, S., additional

Published
2011
Full Text
View/download PDF

15. 7521 POSTER Successful pan-European and trans-Atlantic collaboration in a randomised controlled trial in osteosarcoma: EURAMOS1 (ISRCTN67613327; a trial conducted as part of ECT-EUROCORES)

Author

Whelan, J., primary, Smeland, S., additional, Marina, N., additional, Bernstein, M., additional, Sydes, M.R., additional, May, B., additional, Butterfass-Bahloul, T., additional, Perisoglou, M., additional, Carrle, D., additional, and Bielack, S., additional

Published
2007
Full Text
View/download PDF

18. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII

Author

Smeland, S, primary, Müller, C, additional, Alvegard, T.A, additional, Wiklund, T, additional, Wiebe, T, additional, Björk, O, additional, Stenwig, A.E, additional, Willén, H, additional, Holmström, T, additional, Follerås, G, additional, Brosjö, O, additional, Kivioja, A, additional, Jonsson, K, additional, Monge, O, additional, and Sæter, G, additional

Published
2003
Full Text
View/download PDF

19. Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation

Author

K. Sundby Hall, Lorenza Gandola, A. Tamburini, Mikael Eriksson, Amelia Tienghi, S. Ferrari, Franca Fagioli, Paula Lindholm, Roberto Luksch, Massimo Eraldo Abate, Arcangelo Prete, Sigbjørn Smeland, Giovanni Grignani, P. Picci, Primo Andrea Daolio, M. Podda, Pietro Ruggieri, Enza Barbieri, Gianni Bisogno, Luksch R, Tienghi A, Hall KS, Fagioli F, Picci P, Barbieri E, Gandola L, Erikksson M, Ruggieri P, Daolio P, Linholm P, Prete A, Bisogno G, Tamburini A, Grignani G, Abate ME, Podda M, Smeland S, and Ferrari S.

Subjects
Male, Melphalan, Oncology, Lung Neoplasms, medicine.medical_treatment, Antineoplastic Combined Chemotherapy Protocols, High-dose chemotherapy, Neoplasm Metastasis, Child, Etoposide, Ewing's sarcoma, Sarcoma, Combination chemotherapy, Hematology, Prognosis, Combined Modality Therapy, Primary tumor, Chemotherapy regimen, Vincristine, Child, Preschool, Total-lung irradiation, Female, Lung metastases, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Antineoplastic Agents, Bone Neoplasms, Sarcoma, Ewing, Busulfan, Cyclophosphamide, Humans, Ifosfamide, Myeloablative Agonists, Stem Cell Transplantation, Young Adult, Ewing, Internal medicine, medicine, Preschool, business.industry, medicine.disease, Surgery, Radiation therapy, business
Abstract

Background: The Italian Sarcoma Group and the Scandinavian Sarcoma Group designed a joint study to improve the prognosis for patients with Ewing's family tumors and synchronous metastatic disease limited to the lungs, or the pleura, or a single bone. Patients and methods: The study was opened in 1999 and closed to the enrollment in 2008. The program consisted of intensive five-drug combination chemotherapy, surgery and/or radiotherapy as local treatment, and consolidation treatment with high-dose busulfan/melphalan plus autologous stem cell rescue and total-lung irradiation. Results: During the study period, 102 consecutive patients were enrolled. The median follow-up was 62 months (range 24-124). The 5-year event-free survival probability was 0.43 [standard deviation (SD) = 0.05] and the 5-year overall survival probability was 0.52 (SD = 0.052). Unfavorable prognostic factors emerging on multivariate analysis were a poor histological/radiological response at the site of the primary tumor [relative risk (RR) = 3.4], and incomplete radiological remission of lung metastases after primary chemotherapy (RR = 2.6). One toxic death and one secondary leukemia were recorded. Conclusions: This intensive approach is feasible and long-term survival is achievable in ∼50% of patients. New treatment approaches are warranted for patients responding poorly to primary chemotherapy.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results